Posted by Michael Wonder on 11 Nov 2022
EQRx no longer seeks to disrupt prices in non-small-cell lung cancer space
10 November 2022 - The biotechnology company EQRx no longer seeks to disrupt prices in the non-small-cell lung cancer space.
The company had been developing sugemalimab – a PD-(L)1, checkpoint inhibitor – to compete with other drugs in the therapeutic class. But, due to regulatory hurdles and a change in company strategy, EQRx says it is suspending the sugemalimab program.
